Marine Renewable Energy: Tidal demonstrator to be built

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Marine Renewable Energy: Tidal demonstrator to be built by HydroQuest and the CMN group
  Press release  London, 21 November 2016     Marine Renewable Energy:   Tidal demonstrator to be built by HydroQuest and the CMN group     At the International Tidal Energy Summit , being held in London on November 22 and 23, HydroQuest and CMN (Constructions Mécaniques de Normandie) announce the launch of an innovative demonstration project for the tidal energy sector.   Implemented with support from the University of Caen Normandie, this project involves installing an ocean-based 1 MW hydrokinetic tidal turbine at the Paimpol-Bréhat site, as part of an agreement with EDF, from the second half of 2017.   The project was selected in France's call-for-projects, "Marine renewable energies and pilot river turbine farms", funded by the State in the context of its Investments in the Future Program and operated by ADEME.   The demonstrator's goal is to validate this machine's performance under real operating conditions, with plans for commercialisation on an international scale by 2019.   Pierre Balmer, CEO of CMN, explains: "The partnership surrounding the demonstrator is part of our growth strategy for marine renewable energies, a sector which will become one of the pillars for our company over time, in addition to our historical activity in naval construction. This project, which further solidifies the collaboration we have established with HydroQuest over the past several years, confirms the launch of a French tidal hydrokinetic turbine industry in which we are now present alongside HydroQuest."   Jean-François Simon, CEO of HydroQuest, says: " Being selected by ADEME demonstrates real recognition by the State of our HydroQuest hydrokinetic turbine technology, which has already proven its effectiveness in river scenarios. Following the validation of our demonstrator's operation, our goal will be to implement pilot farms with a few turbines in France and around the world. We will then move forward with the installation of commercial farms starting in 2019, thus participating in the energy transition that is already taking place ."   Technology with high potential for energy and the environment   The HydroQuest Ocean turbine offers many benefits, including:   High performance : with unique technology featuring two vertical axes, free of any prominent central obstacles, the turbine offers efficient hydrodynamic output with nominal power of 1 MW. In addition, this cross-flow turbine is essentially unaffected by current direction, enabling the unit to be fixed to its foundation without any production loss.   Robust design : the all-metal structure improves resistance to water-related constraints while reducing the cost of maintenance operations.   Adjustable height : the machine will be developed with one or two levels to adapt to the various depths of worldwide water resources.   Cost-effectiveness : manufacturing and maintenance costs are reduced, offering one of the best price/MW ratios available for equipment today.   HydroQuest Ocean will be built at CMN workshops in Cherbourg, then ocean-tested under real operating conditions for several months.            
  Press contact - Agency Amalthea Floriane Gouache - +33 (0)4 26 78 27 15 - fgouache@amalthea.fr     About HydroQuest - www.hydroquest.net Based in the heart of the Alps near Grenoble (France), the birth-place of hydroelectricity, HydroQuest was founded in 2010. The company has developed a line of turbines capable of producing electricity from water flows in rivers, estuaries, and oceans. HydroQuest benefits from a solid scientific and technical foundation, leveraging a qualified team of employees including project developers, engineers and PhDs with proven expertise in mechanics, hydrodynamics and electricity, and over ten years of research carried out by four internationally renowned laboratories specialising in hydroelectricity. The company has a portfolio of 9 internationally registered patents developed in partnership with EDF and Grenoble-INP. HydroQuest has already set up several turbines in Grenoble, Orléans and Guiana.   About CMN - www.cmn-group.com CMN (Constructions Mécaniques de Normandie) is a French shipyard specialising in the construction of military and civilian vessels. With operations located for over 60 years in Cherbourg, France, the company's headquarters are in Paris. CMN employs 350 highly qualified people, designing and producing some of the world's most advanced vessels and boiler systems. The company also has a subsidiary specialising in Integrated Logistics Services, based in Newcastle, England. CMN has been involved with the marine turbine sector since 2012.            
Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...7ddb6684bc

Scroll down for more posts ▼

Top 10 Most Recent News Articles

KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 9

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 123

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 52

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 422

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 175

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 104

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 0

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 432

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 287

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 557

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading

Top 5 Most Recently Viewed Articles

NKGen Biotech to Present Innovative Research at Global Congress

Updated Category News Views 157

NKGen Biotech's Exciting Announcement on Upcoming Presentation NKGen Biotech Inc. (NASDAQ: NKGN), a pioneering clinical-stage biotechnology firm dedicated to developing cutting-edge autologous and allogeneic natural killer cell therapies, has recently shared some thrilling news regarding their participation in an international event. Highlighting Neurodegenerative...

Continue Reading
Celebrating Case Managers: A Call to Action for 2025

Updated Category News Views 522

Recognizing the Contribution of Case Managers in 2025 Case managers have proven time and again to be essential contributors to the health and human services spectrum. In 2025, the two prominent organizations in the case management field—the American Case Management Association (ACMA) and the Commission for Case Manager Certification (CCMC)—have once again partnered to...

Continue Reading
Faruqi & Faruqi Investigates Ford Investor Claims

Updated Category News Views 92

Back in 2024, Faruqi & Faruqi took aim at Ford Motor Company (NYSE: F), investigating claims from investors who’d racked up losses over $100,000. They were diving deep into the financial mess at Ford—a colossal vehicle manufacturer that found itself knee-deep in allegations of breaching federal securities laws. The chatter was all about how quality assurance failures...

Continue Reading
Entourage Health Announces Going-Private Arrangement Plan

Updated Category News Views 236

Entourage Health Corp. Takes a Bold Step Toward Going-Private Entourage Health Corp. (TSX-V: ENTG) (OTCQX: ETRGF) has officially entered into a significant arrangement agreement with 1001007762 Ontario Inc. and 2437653 Ontario Inc. This strategic move, a statutory plan under the Business Corporations Act (Ontario), sees the Purchaser agreeing to acquire all common shares...

Continue Reading
A&W Revenue Royalties Income Fund Q3 2024 Results Review

Updated Category News Views 183

A&W Revenue Royalties Income Fund Q3 2024 Financial Overview TRADING SYMBOL: TSX: AW.UN A&W Revenue Royalties Income Fund has reported encouraging results for the third quarter ending this year. The quarterly performance reflects steady royalty income growth and strategic developments that promise an exciting future. Royalty Income Performance In the third quarter of...

Continue Reading